• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    enGene Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    6/10/25 5:26:39 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENGN alert in real time by email
    false000198084500019808452025-06-102025-06-100001980845us-gaap:CommonClassAMember2025-06-102025-06-100001980845engn:CommonSharesMember2025-06-102025-06-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 10, 2025

    enGene Holdings Inc.
    (Exact name of registrant as specified in its charter)


    British Columbia
     
    001-41854
     
    00-0000000
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)

    4868 Rue Levy, Suite 220
    Saint-Laurent, Quebec
     
    H4R 2P1
    (Address of principal executive offices)
     
    (Zip code)

    Registrant's telephone number, including area code (514) 332-4888

    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Shares
    ENGN
    NASDAQ
    Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Common Share
    ENGNW
    NASDAQ

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒


    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    Approval of the enGene Holdings Inc. 2025 Employee Stock Purchase Plan
    As described in Item 5.07 of this Current Report on Form 8-K, on June 10, 2025, at its 2025 Annual General Meeting of shareholders (the “Annual Meeting”), the shareholders of enGene Holdings Inc. (the “Company”) approved the adoption of the 2025 Employee Stock Purchase Plan  (the “ESPP”), pursuant to which 2,000,000 common shares of the Company, no par value (the “Common Shares”), will be reserved for issuance.
    The ESPP is intended to promote the interests of the Company by providing eligible employees with the opportunity to acquire a proprietary interest in the Company through participation in an employee stock purchase plan designed to qualify under Section 423 of the Internal Revenue Code of 1986 (the “Code”) for one or more specified offerings made under the Plan, or where determined appropriate by the Plan Administrator under Section 3(b), outside the requirements of Code Section 423. The number of Common Shares reserved for issuance under the ESPP will be limited to 2,000,000 shares. The shares issuable under the ESPP will be made available from authorized but unissued common shares. Shares that are cancelled, terminated, forfeited, fail to vest, or for any other reason are not paid or delivered under the ESPP will generally be available for subsequent offering periods under the ESPP. The Plan is effective as of June 10, 2025, which was the date of the Annual Meeting.
    For a further description of the terms and conditions of the ESPP, as approved by shareholders, see “Proposal 2: Approval of the 2025 Employee Stock Purchase Plan Proposal” in the Company’s definitive Proxy Statement, as filed with the Securities and Exchange Commission on May 9, 2025 (the “Proxy Statement”), which description is incorporated herein by reference.
    The foregoing description of the ESPP, including the description contained in the Proxy Statement, is qualified in its entirety by reference to the full text of the ESPP, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
    Item 5.07. Submission of Matters to a Vote of Security Holders.
    The Annual Meeting of the Company was held on June 10, 2025 at 8:30 a.m. EDT. A total of 38,101,263 of the Company’s  Common Shares were present or represented by proxy at the Annual Meeting, representing approximately 74.60% of the Company’s 51,070,851 Common Shares that were outstanding and entitled to vote at the Annual Meeting as of the record date of April 29, 2025.
    Set forth below, and pursuant to the requirements set out in subsection 11.3 of National Instrument 51-102, are the final voting results for each of the matters submitted to a vote of the shareholders at the Annual Meeting, which matters are each described in further detail in the Company’s Proxy Statement:
    Proposal 1 – Election of Directors


                 
    Director Nominee
     
    For
     
    Withhold
     
    Broker Non-Votes
    Gerald Brunk
     
    30,481,847
     
    8,154
     
    7,611,262
    Dr. Richard Glickman
     
    26,312,872
     
    4,177,129
     
    7,611,262

    Proposal 2 – Approval of the enGene Holdings Inc. 2025 Employee Stock Purchase Plan


                 
    For
     
    Against
     
    Abstain
     
    Broker Non-Votes
    30,152,713
     
    8,427
     
    328,861
     
    7,611,262
    Proposal 3 – Appointment and Remuneration of Auditor


    For
     
    Withhold
     
    Broker Non-Votes
    38,101,229
     
    34
     
    -

    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits
     
         
    Exhibit Number
      
    Description
       
    10.1
      
    enGene Holdings Inc. 2025 Employee Stock Purchase Plan
       
    104
      
    Cover Page Interactive Data File (Formatted as Inline XBRL)


    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


     
    ENGENE HOLDINGS INC.
     
     
    Date: June 10, 2025
    By:
     /s/ Ronald H. W. Cooper
     
    Name: Ronald H. W. Cooper
     
    Title: Chief Executive Officer


    Get the next $ENGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENGN

    DatePrice TargetRatingAnalyst
    2/18/2025$26.00Overweight
    Piper Sandler
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    12/23/2024$25.00Buy
    H.C. Wainwright
    11/27/2024$23.00Outperform
    Raymond James
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    8/28/2024$30.00Outperform
    Oppenheimer
    4/22/2024$30.00Overweight
    Wells Fargo
    4/15/2024$34.00Buy
    Guggenheim
    More analyst ratings

    $ENGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on enGene Holdings with a new price target

    Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00

    2/18/25 7:08:31 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Holdings downgraded by UBS with a new price target

    UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously

    2/14/25 8:16:16 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on enGene Holdings with a new price target

    H.C. Wainwright initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $25.00

    12/23/24 7:22:45 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

    Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula

    9/30/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

    Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ LEGEND's pivotal cohort data update planned for 4Q 2025 Detalimogene granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA Biologic License Application (BLA) submission planned for 2H 2026 Cash and marketable securities of $224.9 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. "Reaching target enrollment in LEGEND'

    9/11/25 4:03:00 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

    Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achieved enGene plans to provide an update from LEGEND's pivotal cohort in 4Q 2025 Biologic License Application (BLA) submission planned for 2H 2026 enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid ("detalimogene" and previously EG-70) in patients with high-risk, non-muscle invasive bladder cancer (NMIBC). LEGEND's pivotal Cohort 1 is studying detalim

    9/3/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $4,999,993 worth of shares (561,797 units at $8.90) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    11/1/24 4:15:08 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $3,012,674 worth of shares (470,633 units at $6.40) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    10/18/24 4:15:05 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Cooper Ronald Harold Wilfred bought $57,000 worth of shares (10,000 units at $5.70) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    10/1/24 8:02:44 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    SEC Filings

    View All

    SEC Form S-8 filed by enGene Holdings Inc.

    S-8 - enGene Holdings Inc. (0001980845) (Filer)

    9/11/25 4:44:20 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by enGene Holdings Inc.

    10-Q - enGene Holdings Inc. (0001980845) (Filer)

    9/11/25 4:11:26 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - enGene Holdings Inc. (0001980845) (Filer)

    9/11/25 4:08:02 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Regulatory Officer Boyd Matthew Ross

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    7/14/25 4:10:07 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Boyd Matthew Ross claimed ownership of 7,500 shares (SEC Form 3)

    3 - enGene Holdings Inc. (0001980845) (Issuer)

    7/14/25 4:09:12 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Astley-Sparke Philip

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    7/10/25 4:07:16 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Leadership Updates

    Live Leadership Updates

    View All

    enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

    Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula

    9/30/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Announces Board and Leadership Appointments to Support Commercial Readiness

    Philip Astley-Sparke, William Grossman and Michael Heffernan join the Board Management promotions strengthen clinical and regulatory operations Matthew Boyd named Chief Regulatory Officer, Jill Buck Chief Development Officer, and Katherine Chan Executive Director, Urology Clinical Lead enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transit

    7/8/25 8:00:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Names Amy Pott as Chief Global Commercialization Officer

    enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co

    5/28/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Financials

    Live finance-specific insights

    View All

    enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

    Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ LEGEND's pivotal cohort data update planned for 4Q 2025 Detalimogene granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA Biologic License Application (BLA) submission planned for 2H 2026 Cash and marketable securities of $224.9 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. "Reaching target enrollment in LEGEND'

    9/11/25 4:03:00 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

    Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application Cash and marketable securities of $251.5 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. "We have seen strong

    6/12/25 8:00:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Reports First Quarter 2025 Financial Results and Provides Business Update

    Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track Cash and marketable securities of $272.8 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. "With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our pl

    3/10/25 4:05:00 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

    SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

    11/14/24 5:48:15 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

    SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

    11/14/24 5:05:21 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

    SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

    11/14/24 7:53:57 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care